Abstract The purpose of this study was to correlate the pattern of spread with oncological outcomes in advanced ovarian cancer patients. This is a retrospective analysis of 55 consecutive patients who had advanced epithelial ovarian cancer or primary peritoneal carcinomatosis (stages 3C and 4) with primary surgical intervention as the initial modality of treatment. Based on the spread of disease, they were further classified into class A: disease confined to the pelvis (excluded); class B: disease extending to the lower abdomen and omentum; class C: diffuse small-bowel disease with or without A, B, or D; and class D: disease in the upper abdomen. There were 17 patients (30.9%) in class B, 17 (30.9%) in class C, and 21 (38.2%) in class D. The number of patients with suboptimal cytoreduction was highest in class C (six patients). At the end of follow-up (median 38.6 months), 16 patients had no evidence of disease and 26 patients were alive with disease. The 3-year overall survival rates in classes B, C, and D were 94.1, 52.5, and 93.3%, respectively. The 3-year progressionfree survival rates were 55.8, 11.8, and 41.9%, respectively. The rates were lowest for class C. The differences in the overall survival rate (p < 0.001) and progression-free survival rate (p = 0.001) were statistically significant. In advanced ovarian cancer patients, the presence of disease in the small-bowel serosa and mesentery results in poorer outcomes in terms of overall and progression-free survival. The number of patients with suboptimal cytoreduction was also highest in this group.
Introduction
Ovarian cancers are the third most common gynaecological malignancies worldwide. They constitute the fourth commonest malignancy affecting Indian women. According to GLOBOCAN 2012, in India, the estimated incidence and mortality rates were 26,834 (5%) and 19,549 (6%), respectively [1] . The overall prognosis is poor, because 70% of the patients present with advanced disease, stages 3 and 4 [2] . Many studies have demonstrated that optimal surgical cytoreduction to less than 1 cm or no residual disease confers a definite survival benefit to these patients [3] [4] [5] [6] [7] . The surgical cytoreduction rates vary globally, from 22 to 98% [8, 9] . The reasons for suboptimal debulking include diffuse peritoneal carcinomatosis, metastatic deposits in difficult to access areas in the upper abdomen, and the requirement for resection of extensive areas of the bowel. It is not known whether it is the disease distribution which allows optimal cytoreduction or whether the ability to achieve optimal cytoreduction identifies a biologically more favourable patient subgroup or a combination of both. It was our observation that diffuse mesenteric and small-bowel disease probably had lower rates of optimal cytoreduction and therefore poorer survival benefits. However, there are not many studies on primary surgical debulking of diffuse disease over the mesentery and small bowel. A need was felt to analyse the anatomical pattern of spread and the oncological outcomes. The purpose of this study is to correlate the pattern of spread with oncological outcomes in advanced ovarian cancers.
Methods
The study is a retrospective analysis conducted in a tertiary level cancer care centre during 5 years between January 2009 and December 2013. The institutional research board approval was obtained prior to the study. All patients included had advanced epithelial ovarian cancer or primary peritoneal carcinomatosis with primary surgical intervention as the initial modality of treatment. An assessment of the spread of disease at primary surgery was an essential inclusion criterion. This included patients who had initial exploration in the form of a mini laparotomy and biopsy in addition to those who underwent primary debulking surgery. Those who underwent neoadjuvant chemotherapy without an initial exploration followed by interval debulking were excluded from the analysis as neoadjuvant chemotherapy (NACT) alters the disease pattern which is observed at the time of surgery. Patients with early disease (stages 1-3B) were also excluded from the analysis as the survival rates would be altered in early disease. The study cohort included both low-and highgrade carcinoma stages 3C-4. The electronic medical records including clinical records and radiological, pathological, and operative details were studied. A preoperative CT/MRI scan was used to assess spread of the disease and resectability. The feasibility of primary cytoreduction is discussed in the multidisciplinary tumour board for all patients. Those patients in whom optimal cytoreduction is unlikely undergo neoadjuvant chemotherapy. Our policy was to offer NACT for patient with high-grade disease associated with diffuse carcinomatosis as assessed by clinical examination and imaging and also for patients with poor performance status. This centre employs standard surgical techniques to achieve complete cytoreduction. Complex surgical procedures are undertaken when indicated. Lymph node dissection is not done routinely in our centre. However, lymph nodes that are found to be palpable intraoperatively are dissected. A total of 307 patients with ovarian tumour were screened. Fifty-seven patients were treated with neoadjuvant chemotherapy without an initial surgical intervention and were therefore excluded from the study. Twenty-two had disease confined to the pelvis (early stage) and were excluded from the analysis. Fifty-five consecutive patients with advanced epithelial ovarian cancers (stages 3C and 4) who fit the inclusion criteria were identified (Fig. 1) . The anatomical pattern of spread of the tumour in each patient was recorded in detail using an intraoperative mapping tool. Based on the intraoperative mapping of the disease, they were further classified into four classes:
Class A: disease confined to the pelvis (excluded from the study) Class B: disease extending to the lower abdomen and omentum Class C: diffuse small-bowel disease with or without A, B, or D Class D: disease in the upper abdomen (liver, diaphragm, spleen, and pancreas)
The mean follow-up was for 38.6 months (range 6 to 81 months). Descriptive data analysis and Kaplan-Meier curves were used for statistical analysis.
Results
The mean age of the patients was 54.6 years, (range 30-87 years). Table 1 shows the demographics and disease characteristics. Table 2 shows the pattern of spread in different anatomical areas. There were 17 patients (30.9%) in class B, 17 patients (30.9%) in class C, and 21 patients (38.2%) in class D. Forty-eight patients underwent primary surgery followed by adjuvant chemotherapy. Seven patients had laparotomy and biopsy followed by neoadjuvant chemotherapy and debulking surgery. Table 3 shows the residual disease after cytoreductive surgery. Optimal cytoreduction to no residual disease was achieved in 36 patients (65.5%). Table 4 shows the correlation between the residual disease status and the classes of spread. The number of patients with suboptimal cytoreduction was highest in class C (six patients). Out of the 36 patients with optimal cytoreduction, 12 patients (33%) had grades 1 and 2 disease. Table 5 shows the outcome data in terms of recurrences and the status at the end of the follow-up. At the end of the follow-up (median 38.6 months), 16 patients had no evidence of disease and 26 patients were alive with disease. The 3-year overall survival rates in classes B, C, and D were 94.1, 52.5, and 93.3%, respectively. The 3-year progression-free survival rates for classes B, C, and D were 55.8, 11.8, and 41.9%, respectively. The rates were lowest for class C. Figures 2 and 3 show the Kaplan-Meier survival curves for overall survival and progression-free survival, comparing the classes of spread, respectively. The differences in the overall survival rate (p < 0.001) and progression-free survival rate (p = 0.001) were statistically significant.
Discussion
Ovarian cancer metastasises by direct extension from the ovarian/fallopian tumour. The exfoliated cells are transported throughout the peritoneum by physiological peritoneal fluid. Patients usually present with locally advanced disease with contiguous extension to or encasement of the reproductive organs and sigmoid colon. The omentum is almost always transformed by the tumour. The tumour stays within the peritoneal cavity and only invades the mesothelium-lined surfaces [10, 11] . This study analyses whether the anatomical location of the tumour within the peritoneal cavity has any bearing on the outcome of the disease.
The results of the present study showed that, in patients with advanced ovarian cancer, disease on the small-bowel serosa and mesentery was associated with poorer outcomes in terms of overall and progression-free survival. A search of literature showed some related studies about the disease pattern at surgery. In a retrospective analysis of 417 stage 3 patients, cytoreduced to microscopic disease, Hamilton et al. [12] classified the disease into (a) minimal disease, (b) abdominal peritoneal disease, and (c) upper abdominal disease. On multivariate analysis, the upper abdominal disease group had a worse prognosis than the minimal disease and abdominal peritoneal disease groups both individually and combined. This study used a type of classification different from that used in our study. Also, diffuse mesenteric disease was not included in their data. In our study, patients who underwent neoadjuvant chemotherapy without an initial surgical exploration were excluded from the analysis. This was done as chemotherapy alters the disease pattern [13, 14] . Also, disease confined to the pelvis was excluded in our study, as the survival rates would be affected by the earlier stage of the disease [15] .
Zivanovic et al. conducted a retrospective study of 526 patients with International Federation of Gynecology and Obstetrics (FIGO) stage 3C disease who underwent primary cytoreduction [16] . The study group was classified into three, based on the presence and size of disease, cephalad to the greater omentum at the beginning of the operative procedure. On multivariate analysis, patients with bulky upper abdominal disease who underwent optimal cytoreduction had decreased risk of relapse compared to patients who underwent suboptimal cytoreduction. The median progression-free survival of patients who had no visible or palpable upper abdominal disease on exploration was superior to that of patients who had more extensive upper abdominal disease. The outcome of this study is similar to that conducted by Hamilton et al.
Elene et al., in a study of 79 consecutive epithelial ovarian cancer patients who underwent both primary and secondary cytoreduction over a 10-year period, used a validated documentation tool for intraoperative mapping [17] . It was found that secondary cytoreduction is associated with significantly lower optimal tumour debulking rates compared to primary surgery. This is because the disease tends to recur in patterns less accessible to complete resection such as the [18] . The intra-abdominal tumour dissemination pattern, maximal tumour load, tumour residuals, and operative morbidity were evaluated. It was found that tumour expansion in multiple (>4) abdominal quadrants was the major negative predictor for complete tumour resection. The middle abdomen (including the mesentery and splenic or left colic flexure) and the upper abdomen in the region of the porta hepatis had the highest risk of incomplete tumour resection. This study echoes our findings that disease in the middle abdomen including the small-bowel mesentery has unfavourable outcomes. Chereau et al. compared peritoneal carcinomatosis scoring methods in predicting resectability and found that Fagotti-modified score outperformed other scores [19] . In their review of GOG protocol 52, Hoskins et al. showed that the volume of initial extrapelvic disease remained a significant predictor of decreased survival [20] . But this study did not address if further cytoreduction to no gross visible disease could overcome these factors important in predicting survival. 40.5% of patients in the small-volume group had complete gross resection vs 17.1% in the large-volume group. Eisenkop et al. demonstrated that though the total extent of NOS not otherwise specified intra-abdominal tumour burden did independently influence survival, complete surgical resection to microscopic residual had a more significant independent influence on survival [21] . Preoperative identification of patients at high risk of incomplete cytoreduction may allow triaging them into an alternate management-like neoadjuvant chemotherapy. In our study, out of the 112 patients registered as advanced ovarian cancer, 75 patients (68%) actually would have benefitted from primary chemotherapy than primary surgery. Data from the present study suggests that a preoperative identification of diffuse mesenteric/small-bowel involvement by imaging could avoid unnecessary surgery. However, the usefulness of CT/MRI in identification of miliary mesenteric deposits is questionable. Seung et al. [22] constructed a nomogram for predicting incomplete cytoreduction in advanced ovarian cancers. This was done by studying 343 consecutive ovarian cancer patients who underwent PET CT before primary surgery. Both PET CT features and surgical aggressiveness index of individual surgeons were used in constructing the nomogram. However, the use of PET scan for routine imaging before surgery is not an accepted evidence-based practice. Mesenteric tumour implants as depicted on CT and MRI and tumour involvement of the porta hepatis, the lesser sac, or the root of the small-bowel mesentery have broadly been identified as markers of unresectability in primary EOC [23] . Potential predictors of cytoreducibility might include tumour location and size and mesenteric disease [24] . Suidan et al. in their prospective, multicentre trial of 350 patients who underwent primary cytoreduction of stages 3-4 ovarian cancers assessed preoperative CT scans and CA 125 values. They identified nine criteria associated with suboptimal cytoreduction and developed a model to predict suboptimal debulking [25] . Out of the 36 patients in whom optimal cytoreduction to no residual disease was achieved in our series, 12 patients (33%) had grades 1 and 2 disease. It is known that low-grade type 1 ovarian cancers, typically present in young women, respond better to surgery and have a relatively good prognosis, despite being resistant to chemotherapy. They also have high prevalence of KRAS and BRAF mutations [26] . ER/PR receptor status was not checked in our series. Receptor-positive patients may benefit from regimes like letrozole or tamoxifen especially in young patients with grades 1 and 2 disease. Our institute does [27] . Survival improved with increasing number of IP cycles. The other implication of this study is in the use of molecular markers to predict optimal cytoreduction. For instance, Pcadherin expression is more in suboptimally resected tumours. Receptor-type tyrosine phosphatase F was also differentially expressed in association with optimal cytoreductive surgery [28] . Data from similar studies could be used to validate the use of molecular markers in predicting optimal cytoreduction.
The strength of this study is that it is a single-institution analysis with a short inclusion period. Therefore, it reduces bias caused by change of treatment. A limitation is the retrospective and non-randomized design and the short follow-up of 36 months. This study is an audit of practice of the surgical management of advanced ovarian cancers in our institute. An attempt has been made to find out the resectability and oncological outcomes when there is diffuse disease on the smallbowel mucosa and mesentery. However, a definitive conclusion about the PFS and OS in this group requires a larger number of patients to be recruited for the study.
Conclusion
In advanced ovarian cancer patients, the presence of disease on the small-bowel serosa and mesentery may be associated with poor oncological outcomes. The number of patients with suboptimal cytoreduction is high in this group. However, larger studies are required for reaching a definitive conclusion. We must continue to develop techniques whereby diffuse disease on the small-bowel serosa and mesentery is better predicted preoperatively by imaging. Laparoscopic Fagotti scoring could predict incomplete cytoreduction associated with small-bowel disease. This subgroup may benefit from NACT rather than a primary surgery with gross residual disease. Further prospective studies could throw light on whether diffuse small-bowel disease and mesenteric disease can be predicted preoperatively by imaging or molecular markers.
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